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Introduction
Hypertrophic cardiomyopathy (HCM) is generally
regarded as a disease characterized by substantial left ven-
tricular (LV) wall thickening, often with extensive hyper-
trophy diffusely involving the LV chamber. This
impression has been based on traditional non-tomo-
graphic imaging with two-dimensional echocardiogra-
phy. However, CMR has certain advantages for more
precisely defining LV hypertrophy and the phenotypic
expression of HCM.
Purpose
To define the distribution and pattern of LV wall thicken-
ing in HCM using CMR.
Methods
CMR was performed in 82 consecutive HCM patients (42
± 16 years; 71% male) from two HCM referral centers.
ECG-gated, breath-hold cine images were acquired in 3
long-axes and contiguous 10 mm thick short-axis slices,
achieving full LV coverage. LV was divided into 16 seg-
ments based on the established AHA model. For each
short-axis cross-sectional level of the LV (basal, mid, api-
cal) the greatest wall thickness measurement was calcu-
lated in each wall segment. LV hypertrophy was defined as
wall thickness ≥ 15 mm and: focal when confined to ≤ 2
contiguous segments (≤ 12% of LV), intermediate if
present in 3–7 segments (13–49% of LV) and diffuse when
present in ≥ 8 segments (≥ 50% of LV).
Results
Maximal LV wall thickness was 22 ± 4.5 mm (range 15 to
36 mm). Basal anterior septum and contiguous anterior
free wall were the most common areas. Distribution and
extent of hypertrophied LV segments was focal in 16
(19%), intermediate in 30 (35%) and diffuse in 39
(46%). Sixteen patients (19%) also had areas of non-con-
tiguous LV hypertrophy separated by regions of normal
thickness. A significant relationship was evident between
the number of hypertrophied LV segments and total LV
mass (r2 = 0.6; p < 0.001). However, no correlation was
evident between distribution of LV hypertrophy and a
variety of demographic and clinical variables including:
gender (p = 0.5), age (p = 0.9), LV outflow obstruction ≥
30 mmHg (p = 0.1) or heart failure class (p = 0.2).
Conclusion
HCM has been traditionally regarded as a disease charac-
terized by marked and diffuse hypertrophy. However, the
present CMR data provide a novel perspective on the
HCM phenotype with the majority of patients showing
relatively localized LV hypertrophy involving only 10–
50% of LV. The patterns of LV hypertrophy as identified
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by CMR, showed no relationship to the magnitude of
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